Literature DB >> 14972453

Umbilical vein and placental vessels from newborns with hereditary haemorrhagic telangiectasia type 1 genotype are normal despite reduced expression of endoglin.

N L M Chan1, A Bourdeau, S Vera, S Abdalla, M Gross, J Wong, U Cymerman, A D Paterson, B Mullen, M Letarte.   

Abstract

Hereditary haemorrhagic telangiectasia, HHT, is an autosomal dominant disorder that affects approximately 1 in 8000 people. HHT1 is associated with mutations in the ENG (Endoglin) gene and with haploinsufficiency. The disorder is characterized by focally dilated vessels, which can lead to arteriovenous malformations and serious complications even in young children. In the current study, umbilical cord and placenta samples from newborns with ENG mutations were analyzed to estimate the level of corresponding protein and look for potential vascular dysplasia. We confirmed, using metabolic labelling and flow cytometry, that endoglin levels were significantly reduced to median values of 47 per cent (range 32-56 per cent) and 58 per cent (46-90 per cent), respectively, in human umbilical vein endothelial cells derived from newborns with ENG mutations (HHT1 group; n=18) relative to samples from newborns shown not to have the familial mutation (non-HHT group). We also quantified the relative expression of endoglin by estimating the endoglin/PECAM-1 staining ratio in tissue sections. We observed significantly lower values in the HHT1 group, compared to the non-HHT group for the umbilical vein (n=9; median 0.6 vs 0.9; ranges 0.2-1.0 and 0.5-1.5) and for placental stem villus vessels (n=9 and 10; median 0.42 vs 0.93; ranges 0.24-0.58 and 0.56-1.18). No differences in the estimated umbilical vein cross-sectional area and in the proportion of vessels present in placental villi were observed in sections from the HHT1 group relative to the non-HHT group. Thus, blood vessels from HHT1 individuals are maintained intact in the umbilical vein and placenta during pregnancy and delivery, despite a significant reduction in endoglin expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972453     DOI: 10.1016/S0143-4004(03)00181-4

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  4 in total

1.  Immunohistochemical analysis of a merkeloma observed in a patient affected by hereditary haemorrhagic telangiectasia.

Authors:  Elisa Rossi; Laura Boeri; Patrizia Morbini; Fabio Pagella; Andrea Colombo; Elina Matti; Carla Olivieri; Vincenzo Villanacci; Antonella Minelli; Elisabetta Buscarini; Cecilia Canzonieri; Cesare Danesino
Journal:  BMJ Case Rep       Date:  2010-02-08

2.  Vascular defects associated with hereditary hemorrhagic telangiectasia revealed in patient-derived isogenic iPSCs in 3D vessels on chip.

Authors:  Valeria V Orlova; Dennis M Nahon; Amy Cochrane; Xu Cao; Christian Freund; Francijna van den Hil; Cornelius J J Westermann; Repke J Snijder; Johannes Kristian Ploos van Amstel; Peter Ten Dijke; Franck Lebrin; Hans-Jurgen Mager; Christine L Mummery
Journal:  Stem Cell Reports       Date:  2022-06-30       Impact factor: 7.294

3.  Effective Label-Free Sorting of Multipotent Mesenchymal Stem Cells from Clinical Bone Marrow Samples.

Authors:  Silvia Zia; Carola Cavallo; Ilaria Vigliotta; Valentina Parisi; Brunella Grigolo; Roberto Buda; Pasquale Marrazzo; Francesco Alviano; Laura Bonsi; Andrea Zattoni; Pierluigi Reschiglian; Barbara Roda
Journal:  Bioengineering (Basel)       Date:  2022-01-22

4.  Markers for characterization of bone marrow multipotential stromal cells.

Authors:  Sally A Boxall; Elena Jones
Journal:  Stem Cells Int       Date:  2012-05-14       Impact factor: 5.443

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.